# The Potential of Camostat in COVID-19

> **NCT04625114** · PHASE2 · TERMINATED · sponsor: **University Hospital, Ghent** · enrollment: 108 (actual)

## Conditions studied

- Covid19

## Interventions

- **DRUG:** Camostat
- **DRUG:** Placebo
- **DRUG:** Camostat
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04625114
- **Lead sponsor:** University Hospital, Ghent
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-11-04
- **Primary completion:** 2022-07-12
- **Final completion:** 2022-07-12
- **Target enrollment:** 108 (ACTUAL)
- **Why stopped:** Interim analyses did not show evidence that camostat mesylate under the present conditions (300 mg three times daily for five or 10 consecutive days, fasted state) was effective as an antiviral drug against early phase SARS-CoV-2 disease.
- **Last updated:** 2024-08-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04625114

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04625114, "The Potential of Camostat in COVID-19". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT04625114. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*